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AbsTrACT
Objectives genome- wide meta- analyses of clinically 
defined gout were performed to identify subtype- 
specific susceptibility loci. Evaluation using selection 
pressure analysis with these loci was also conducted to 
investigate genetic risks characteristic of the Japanese 
population over the last 2000–3000 years.
Methods Two genome- wide association studies 
(gWass) of 3053 clinically defined gout cases and 4554 
controls from Japanese males were performed using the 
Japonica array and illumina array platforms. about 7.2 
million single- nucleotide polymorphisms were meta- 
analysed after imputation. patients were then divided 
into four clinical subtypes (the renal underexcretion type, 
renal overload type, combined type and normal type), 
and meta- analyses were conducted in the same manner. 
selection pressure analyses using singleton density score 
were also performed on each subtype.
results in addition to the eight loci we reported 
previously, two novel loci, PIBF1 and ACSM2B, 
were identified at a genome- wide significance level 
(p<5.0×10–8) from a gWas meta- analysis of all gout 
patients, and other two novel intergenic loci, CD2- 
PTGFRN and SLC28A3- NTRK2, from normal type gout 
patients. subtype- dependent patterns of manhattan plots 
were observed with subtype gWass of gout patients, 
indicating that these subtype- specific loci suggest 
differences in pathophysiology along patients’ gout 
subtypes. selection pressure analysis revealed significant 
enrichment of selection pressure on ABCG2 in addition to 
ALDH2 loci for all subtypes except for normal type gout.
Conclusions our findings on subtype gWas meta- 
analyses and selection pressure analysis of gout will 
assist elucidation of the subtype- dependent molecular 
targets and evolutionary involvement among genotype, 
phenotype and subtype- specific tailor- made medicine/
prevention of gout and hyperuricaemia.
Key messages
What is already known about this subject?
 ► Our previous genome- wide association study 
(GWAS) was performed on broad subtypes of 
gout with only 945 gout cases. A recent study 
has revealed genetic adaptive evolution of gout 
in the Japanese population.
What does this study add?
 ► This is the first GWAS meta- analyses of clinically 
defined gout with more finely differentiated 
subtypes using two GWAS platforms with 
larger samples (3055 cases and 4554 controls). 
We identified multiple subtype- specific loci 
including four novel loci such as CD2, which 
encodes a well- known surface antigen found on 
all peripheral blood T- cells.
 ► The present study showed significant 
enrichment of selection pressure on two genes, 
ABCG2 and ALDH2, for gout susceptibility in the 
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Table 1 Subtypes of gout* used in the present study
subtype Clinical parameters
Differentiated subtype
  RUE type gout FEUA <5.5% and UUE ≤25
  ROL type gout FEUA≥5.5% and UUE >25
  Combined type gout FEUA <5.5% and UUE >25
  Normal type gout FEUA≥5.5% and UUE ≤25
Broader subtype   
  RUE gout (RUE type gout +combined type gout) FEUA <5.5%
  ROL gout (ROL type gout +combined type gout) UUE >25
*Subtypes of hyperuricaemia can be classified in the same manner.
FEUA, fractional excretion of uric acid (unit: %); ROL, renal overload; RUE, renal 
underexcretion; UUE, urinary urate excretion (unit: mg/h/1.73 m2).
Key messages
How might this impact on clinical practice or future 
developments?
 ► Our subtype GWASs of gout enabled us to develop subtype- 
dependent molecular targets that will lead to novel 
subtype- specific genome tailor- made therapies for gout/
hyperuricaemia.
 ► The present study also elucidates the Japanese genetic 
evolution of susceptibility to gout/hyperuricaemia and its 
subtypes.
InTrOduCTIOn
Gout is a well- known disease that manifests as acute and severe 
non- infectious arthritis.1 2 According to patients’ clinical param-
eters which reflect its causes,2–5 gout can be classified into four 
distinct subtypes: the renal underexcretion (RUE) type, renal 
overload (ROL) type, combined type and normal type, as 
shown in table 1 and online supplementary figure S1. Because 
these subtypes reflect causes of gout, genome- wide association 
studies (GWASs) of these subtypes are also likely to indicate 
its various genetic and pathophysiological backgrounds. While 
dividing patients into these subtypes is helpful for understanding 
patients’ pathophysiology, GWASs of these subtypes have only 
rarely been conducted, partly because clinical data, including 
time- consuming urinary collection, are necessary to categorise 
these subtypes. We previously performed a GWAS with clini-
cally defined gout patients,6 followed by another with broader 
subtypes:7 RUE gout and ROL gout (table 1 and online supple-
mentary figure S1), that revealed their specific loci. Although 
we were able to show these associations, this process has its 
limitations, including the use of a custom chip for replication 
studies that did not provide comprehensive genetic association 
searching. We use finely differentiated subtypes in daily clinical 
settings but there were not sufficient numbers of patients in the 
previous study7 to enable a GWAS with these finely differenti-
ated subtypes. This prompted us to conduct, for the first time, 
GWASs with four distinct subtypes using meta- analysis across 
two GWAS platforms with a larger number of patients. We addi-
tionally conducted selection pressure analysis of the Japanese 
population on gout subtypes with the risk loci identified in the 
present study in order to investigate the evolutionary selective 
pressure on the Japanese population over the last 2000–3000 
years.
MeTHOds
study subjects and patients involvement
We performed subtype genome- wide meta- analyses based on 
two case–control data sets for gout that included the Japonica 
Array8 and Illumina Array platforms. Patients with known clin-
ical parameters were recruited from Japanese male outpatients 
at gout clinics (see online supplementary methods). All 3104 
cases were clinically diagnosed as having primary gout according 
to the criteria established by the American College of Rheuma-
tology,9 and their subtypes were also diagnosed along with their 
clinical parameters as described previously3 5 6 (table 1 and online 
supplementary figure S1). As controls, 6081 individuals were 
assigned from Japanese male participants in the Japan Multi- 
Institutional Collaborative Cohort Study (J- MICC Study).10 11 
This research was done without patient involvement (see online 
supplementary methods).
Genotyping and imputation for the Japonica Array data set
A total of 1048 male clinically defined gout cases and 1179 male 
controls from the J- MICC Study10 11 were genotyped with the 
use of a Japonica SNP Array.8 The detail of quality control is 
described in online supplementary methods. This quality control 
filtering resulted in the selection of 1028 case subjects and 1167 
control subjects as well as 603 009 single- nucleotide polymor-
phisms (SNPs). Prephasing and imputation were performed 
using SHAPEIT212 and Minimac3,13 respectively. Postimpu-
tation quality control was also performed as described in the 
online supplementary methods. Ultimately, 1028 case subjects 
and 952 control subjects as well as 7 529 176 SNPs remained for 
the GWAS analysis.
Genotyping and imputation for the Illumina Array data set
As case data, 2056 male gout cases subjects were genotyped with 
the use of HumanOmniExpress or HumanOmniExpressExome 
BeadChip Arrays (Illumina, San Diego, CA, USA). The detail 
of quality control is described in the online supplementary 
methods. This quality control filtering resulted in the selection 
of 2032 case subjects and 4901 control subjects as well as 553 
321 SNPs. Postimputation quality control was also performed 
as described in the online supplementary methods. Ultimately, 
2025 case subjects and 3602 control subjects as well as 7 356 
207 SNPs remained for the GWAS analysis.
Association analysis for snPs and gout
The association of SNPs with gout was assessed using logistic 
regression analysis (generalised linear model); the dependent 
variable was gout label (case=1, control=0), and the indepen-
dent variables included imputed genotypes of each SNP and 
covariates. The covariates comprised the first four principal 
component scores. The effect sizes and standard errors estimated 
in logistic regression analysis were used in the subsequent meta- 
analysis. The association analysis was performed with the use 
of Efficient and Parallelizable Association Container Toolbox 
(EPACTS). https:// genome. sph. umich. edu/ wiki/ EPACTS).
Meta-analyses
The meta- analyses were performed using a total of 3053 cases 
and 4554 controls from the two data sets (online supplemen-
tary table S1–S3). The association results for each SNP across 
the studies were combined with METAL software14 using the 
fixed- effects inverse- variance- weighted method. Heterogeneity 
of effect sizes was assessed via the I2 index. The meta- analysis 
included 7 206 774 SNPs and the results from both the Japonica 
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Figure 1 Manhattan plots of GWASs of subtypes of gout. Clinical subtypes and Manhattan plots of GWASs of all gout types, RUE type gout, 
combined type gout, ROL type gout and normal type gout are shown. The x- axis represents chromosomal positions and the y- axis shows −log10 p 
values. The dotted lines indicate the genome- wide significance threshold (p=5.0×10–8). FEUA, fractional excretion of uric acid (%); GWASs, genome- 
wide association studies; ROL, renal overload; RUE, renal underexcretion; UUE, urinary urate excretion (mg/h/1.73 m2). See table 1 and online 
supplementary figure S1 for a detailed classification of gout/hyperuricaemia.
and Illumina Arrays. The genome- wide significance level α was 
set to a p value of <5×10–8.
Genetic correlation analysis
Genetic correlation analysis using linkage disequilibrium score 
(LDSC) regression analysis15 was conducted to examine the 
potential genetic overlap between gout subtypes and between 
each subtype and serum uric acid (SUA) levels. For the regres-
sion, we used the 1000 genomes phase_3 East Asian LDSC and 
summary statistics for high- quality common SNPs present in the 
HapMap 3 reference panel for each analysis.
selection pressure analysis
The details of genome- wide recent natural selection signature 
using singleton density score (SDS)16 from high- depth whole 
genome sequence data of the Japanese population had been 
described in the previous study.17 Using the same approach,17 we 
calculated the SDS of gout- risk variants identified in the present 
study, and evaluated overlaps between enrichment of the natural 
selection signatures and these variants from each subtype.
resulTs
subtype GWAss of gout
Figure 1 displays Manhattan plots of all and four clinical 
subtypes of gout, and figure 2 shows regional plots of novel loci. 
Compared with the plotted pattern for all clinically defined gout 
patients, each gout subtype (RUE type, ROL type, combined 
type and normal type) shows a subtype- specific plotted pattern 
and indicates the presence of cause- specific associated genes such 
as SLC2A9 and ABCG2. Table 2 lists the genome- wide significant 
loci from subtype GWASs. In total, 10, five, two, seven and three 
loci were identified at the genome- wide significant level to be 
associated with all, the RUE type, ROL type, combined type and 
normal type gout, respectively. Of these, two loci from all gout 
types, rs76499759 of PIBF1 and rs9926388 of ACSM2B, and 
another two intergenic loci from normal type gout, rs146978188 
of CD2- PTGFRN and rs548944057 of SLC28A3- NTRK2, were 
detected as novel loci.
For all gout cases (table 2), 10 loci showed associa-
tion at the genome- wide significance level: rs4148155 of 
ABCG2 (pmeta=1.81×10
–101; ORs=2.23), rs671 of ALDH2 
(pmeta=3.19×10
–54; OR=1.93), rs3775946 of SLC2A9 
(pmeta=3.73×10
–41; OR=1.63), rs145954970 of SLC22A11 
(pmeta=2.25×10
–21; OR=12.43), rs3129500 of FAM35A 
(recently renamed as SHLD2, pmeta=4.34×10
–17; OR=1.37), 
rs1260326 of GCKR (pmeta=2.07×10
–13; OR=1.30), rs1010269 
of BCAS3 (pmeta=1.81×10
–9; OR=1.24), rs2817188 of 
SLC17A1 (pmeta=1.06×10
–8; OR=1.35), rs9926388 of 
ACSM2B (pmeta=2.30×10
–8; OR=1.24) and rs76499759 of 
PIBF1 (pmeta=2.79×10
–8; OR=1.27). Among these 10 loci, 
PIBF1 and ACSM2B (table 2 and figure 2A,B). were identified 
for the first time as gout- risk loci at the genome- wide signif-
icance level. BCAS3 was identified here for the first time by 
the GWAS approach with Japanese individuals, while Li et al18 
reported that rs11653176, another SNP of BCAS3, is associated 
with gout based on a GWAS with a Han Chinese population. We 
also replicated its association with gout in a Japanese population 
using a candidate gene approach.19 Other loci have been previ-
ously reported to have an association with gout in our previous 
GWASs6 7 and association studies.20 21 As suggestive loci for gout, 
seven loci: PDZK1, TACR1- EVA1A, LOC100128993, ARID5B, 
TOLLIP- AS1- BRSK2, SLC38A1 and MLXIP, were detected 
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Figure 2 Regional association plots of novel gout loci. Two loci were revealed to exceed the genome- wide significance level from the meta- analysis 
of GWASs from all gout patients, and another two loci from normal type gout patients. The highest association signal in each panel is located on (A) 
PIBF1, (B) ACSM2B, (C) CD2- PTGFRN and (D) SLC28A3- NTRK2. The region within 1 Mb from the single- nucleotide polymorphism (SNP) indicating 
the lowest p value is shown. (Upper panel) Plots of −log10 p values for the test of SNP association with gout. The SNP showing the lowest p value in 
the meta- analysis is depicted as a purple diamond. Other SNPs are colour- coded according to the extent of linkage disequilibrium (measured in r2) 
with the SNP showing the lowest p value. Recombination rates (centimorgans per Mb) estimated from HapMap Phase II data are also plotted. (Lower 
panel) RefSeq genes. Genomic coordinates are based on NCBI human genome reference sequence build hg19. The r2 data were calculated with 1000 
Genomes Project Phase_3 JPT samples.45 GWASs, genome- wide association studies.
(see online supplementary table S4). Of these, PDZK1, a gene 
encoding a scaffolding protein22 23 such as for urate transporters 
SLC22A12/URAT1 and ABCG2, was reported to have an asso-
ciation with SUA by a GWAS approach24 25 and with gout as a 
result of candidate gene approach studies.26–28
As shown in online supplementary table S2, all the 3053 cases 
were classified into RUE type gout (654 cases), ROL type gout 
(486 cases), combined type gout (905 cases) and normal type 
gout (92 cases) for GWASs of gout subtypes.
The meta- analysis of a GWAS of the RUE type gout (table 2) 
showed significant SNPs in the following five loci: rs3775948 
of SLC2A9 (pmeta=8.01×10
–22; OR=1.89), rs4148155 of 
ABCG2 (pmeta=2.54×10
–16; OR=1.69), rs4646776 of ALDH2 
(pmeta=5.80×10
–16; OR=1.86), rs9420434 of GLUD1 
(pmeta=8.62×10
–11; OR=1.54) and rs76741582 of SLC22A11 
(pmeta=1.06×10
–10; OR=3.93). Since GLUD1 is in LD with 
SHLD2/FAM35A, for which we previously showed a significant 
association with gout,7 all of these five loci were previously iden-
tified as having an association with gout.6 7 We also detected nine 
suggestive loci: SMYD3, GCKR- C2orf16, SMARCC1, FRMD4B- 
MITF, ARL4A- ETV1, C7orf66- EIF3IP1, ASB10, PXDNL and 
LOC100287896- POLD3, for RUE type gout as shown in online 
supplementary table S4.
From ROL type gout (table 2), rs4148155 of ABCG2 
(pmeta=9.75×10
–46; OR=2.79) and rs11066008 of ACAD10 
(ALDH2) (pmeta=4.20×10
–12; OR=1.79) were revealed to have 
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an association. We had previously reported both to have a signif-
icant association with gout.6 7 20 21 Three suggestive loci, CNPY4, 
GRID1 and KCNJ2- CASC17, were also identified from ROL 
type gout (see online supplementary table S4).
Combined type gout displayed the following seven signif-
icant loci (table 2): rs74904971 of ABCG2 (pmeta=1.53×10
–
56; OR=2.46), rs116873087 of NAA25 (pmeta=1.88×10
–27; 
OR=2.38), rs3775948 of SLC2A9 (pmeta=1.43×10
–19; 
OR=1.67), rs6586063 of SHLD2/FAM35A (pmeta=4.30×10
–11; 
OR=1.49), rs9905274 of BCAS3 (pmeta=5.62×10
–9; OR=1.37), 
rs11231879 of CDC42BPG (pmeta=7.66×10
–10; OR=1.44) 
and rs1260326 of GCKR (pmeta=1.05×10
–8; OR=1.37). There 
are studies on these which report an association between 
CDC42BPG and hyperuricaemia from the Japanese exome- wide 
association study,29 and GWAS on SUA from a Korean popula-
tion.30 The significance around rs11231879 of CDC42BPG was, 
however, no longer evident when conditioned on rs11231879 
itself, nor when conditioned on the secondarily significant SNP, 
rs56093838 of SLC22A12/URAT1, demonstrating that these 
signals were from the same locus (see online supplementary 
figure S2). Because URAT1 is a well- known urate transporter 
that markedly affects SUA level, these findings indicate that the 
true associated gene for combined type gout on chromosome 
11q13.1 locus is not CDC42BPG, but SLC22A12/URAT1. 
rs116873087 of NAA25 is in strong LD with rs671 of ALDH2 
(r2=0.97 in the 1000 Genomes Project Phase_3: JPT samples). 
All of the seven loci had therefore been previously identified 
as having an association with gout.6 7 20 21 Two suggestive loci, 
NCKAP5- MIR3679 and PRDM8- FGF5, were also identified 
from combined type gout (see online supplementary table S4).
Three significant loci were found from normal type 
gout: rs548944057 of SLC28A3- NTRK2 (pmeta=2.91×10
–8; 
OR=4.04), rs4148155 of ABCG2 (pmeta=3.64×10
–8; OR=2.34) 
and rs146978188 of CD2- PTGFRN (pmeta=4.93×10
–8; 
OR=6.31). Of these, two intergenic loci are novel suscepti-
bility loci for gout (table 2 and figure 2C,D) There were eight 
suggestive loci: ZNF639- MFN1, RUNX2- CLIC5, DST, HGF, 
MED27- NTNG2, LINC00944- LINC02372, SV2B and GABPA, 
for normal type gout as shown in online supplementary table S4.
The LDSC regression analysis was performed to examine the 
potential genetic overlap between gout subtypes and between 
each subtype and SUA levels. Significant positive genetic correla-
tions were observed among these subtypes as well as between 
these traits and SUA levels (see online supplementary figure S3).
selection pressure analysis of gout susceptibility
We also performed selection pressure analysis of gout on the basis 
of a previous report on the recent natural selection signature in 
the Japanese population.17 This analysis enables us to elucidate 
the genetic risks of gout characterised in the recent evolutionary 
history (2000–3000 years) of the Japanese population. Because 
ALDH2 was reported to be subjected to strong selection pressure 
in the Japanese population,17 and because ABCG2,31 32 as well as 
ALDH2,20 21 33 is a well- known strong susceptible gene for gout 
in Japanese, selection pressure analysis was initially performed 
outside of these two loci. As a result, only combined type gout 
showed significant enrichment of selection pressure (p=0.026; 
figure 3 and online supplementary table S5). When the ABCG2 
locus was included in the analysis, all of these subtypes except 
for normal type gout then showed significant enrichment of 
selection pressure. As expected, analysis including ALDH2 and 
outside of ABCG2 showed significant enrichment of selection 
pressure except for normal type gout. This trend also persisted in 
the analysis with all associated SNPs (figure 3 and online supple-
mentary table S5).
dIsCussIOn
We previously performed GWASs of clinically defined gout cases 
in the Japanese population and found loci including ABCG2, 
SLC2A9, ALDH2 (CUX2), GCKR and SHLD2/FAM35A to be 
associated with gout at a genome- wide significant level.6 7 While 
our previous study was performed with broader subtypes, it is 
one of the unique points of this study that the present GWAS 
is the first to be conducted with four differentiated subtypes: 
the RUE type, ROL type, combined type and normal type gout 
(figure 1), which are commonly used in daily clinical settings. 
Two platforms for GWASs and meta- analyses between them were 
used to perform a comprehensive genetic association search.
The results allowed four novel loci to be identified from the 
present study. The pathophysiological associations of the two 
novel loci from all gout types, PIBF1 and ACSM2B with gout, are 
totally unknown. PIBF (progesterone- induced blocking factor) is 
induced by progesterone and is a mediator that exerts substan-
tial antiabortive activities, including cytokine secretion.34 PIBF1 
might be therefore involved in decreased urate production by 
female hormone and/or decreased inflammatory response to 
gout attack. ACSM2B (acyl- CoA synthetase medium chain 
family member 2B) is a predominant transcript in the human 
liver and an enzyme catalysing the activation of medium- chain 
length fatty acids.35 Because ASCM2B is involved in the produc-
tion of ATP, a purine body metabolised to urate, ASCM2B might 
contribute to gout via that mechanism. While the present study 
showed significance at SNPs of two genes, it is of course possible 
that these are mere markers and that the true risk SNPs are 
present close by. For example, since UMOD, a causative gene 
of uromodulin- associated kidney disease (previously known as 
familial juvenile hyperuricemic nephropathy)36 is located 180 kb 
downstream from rs9926388 of ACSM2B, there might be a rela-
tionship between them.
Another two intergenic loci from normal type gout, 
rs146978188 of CD2- PTGFRN and rs548944057 of SLC28A3- 
NTRK2, were detected for the first time to have an association 
with gout. CD2 is well known as a surface antigen found on 
all peripheral blood T- cells, and PTGFRN/CD9P-1 encodes 
prostaglandin F2 receptor inhibitor. Neither of these was previ-
ously known to have an association with gout or uric acid. 
CD101, which is next to PTGFRN (150 kb downstream from 
rs146978188), is reported to be expressed on macrophages/
monocytes and T- cells, to confer a modulatory/coregulatory 
function, and to be conspicuously downregulated in rheumatoid 
arthritis patients.37 Because macrophages are a chief contributor 
to gouty attack, CD101 might be the true susceptible gene for 
normal type gout. rs146978188 is also in LD with an SNP of 
SLC22A15/FLIPT1, an orphan transporter gene in the same 
family as SLC22A12/URAT1, a well- known urate transporter 
gene that is strongly associated with gout. This transporter gene 
might have an association with normal type gout. SLC28A3/
CNT3 is reported to be an Na+- dependent pyrimidine- selective 
and purine- selective transporter found predominantly in the 
intestine and kidney,38 39 which are the main urate excretion 
pathways. Further analysis is needed to elucidate the relation-
ship between this transporter gene and gout, including normal 
type gout.
While the present study revealed only suggestive loci from 
other subtype GWASs, some of these loci from subtype gout 
also suggest a relationship with RUE, extra- RUE and/or 
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Figure 3 Overlap between natural selection signatures and genetic risk of gout and its subtypes in the Japanese population. For each trait, inflation 
of the selection χ2 value is indicated along the x- axis, and −log10(p) of enrichment is plotted along the y- axis. The horizontal grey line represents 
significance threshold (p<0.05). Because ABCG2 and ALDH2 are associated with a well- known genetic risk of gout in Japanese individuals, selection 
pressure analyses without these loci were performed initially (filled circle), and subsequent analyses were conducted with ABCG2 (filled triangle), 
as well as ABCG2 and ALDH2 (filled square). When calculated with ABCG2 (outside of ALDH2) (filled triangle), all but normal type gout showed 
significant selective pressure, indicating that ABCG2 is involved in adaptive evolution in Japanese for having higher SUA levels, which can result in 
gout. Finally, all but normal type gout also showed significant selective pressure with ABCG2 and ALDH2 loci (filled square). ROL, renal overload; RUE, 
renal underexcretion; SDS, singleton density score; SNPs, single- nucleotide polymorphisms.
overproduction of urate, because gout subtypes reflect their 
clinical parameters (table 1). GWASs with these subtypes should 
therefore be useful for estimating the expression and function of 
proteins encoded by identified loci. rs557868370 of SLC38A1, 
a transporter gene, was detected as a suggestive locus (see online 
supplementary table S4). Since there is a study reporting the 
relationship between oxidative stress and SLC38A1/SNAT1,40 
it might have a relationship with urate, which also has antiox-
idative stress effects. Because genetic variants in urate trans-
porter genes such as ABCG2, SLC2A9 and SLC22A12 are well 
known to cause SUA variation and gout, it is also possible that 
the SLC38A1/SNAT1 transporter is involved in urate or purine 
transport.
Very recently, Tin et al41 performed transancestry GWAS meta- 
analysis of SUA and gout, including self- reported gout cases. We 
compared these SNPs and found five of the 10 loci detected here 
(GCKR, SLC2A9, ABCG2, SLC17A1 and BCAS3) to be associ-
ated with gout (see online supplementary table S6), indicating 
population differences in the genetic basis of gout.
Taking into account the evidence of shared genetic back-
ground among gout subtypes (see online supplementary figure 
S3) and the presence of subtype- specific genetic factors of gout 
(figure 1, table 2), these results will provide helpful information 
for the development of novel subtype- specific genome tailor- 
made medicines and/or prevention for gout and hyperuricaemia.
Adaptive evolution results from adaptation to environmental 
changes over generations. Selection pressure analysis using 
SDS in the present study has elucidated which genes have been 
involved in adaptive evolution over the last 2000–3000 years 
in the Japanese population. The results revealed that the Japa-
nese population has evolved to have higher SUA levels, which 
can result in gout, due to the ABCG2 locus in addition to the 
already- known ALDH2 gene. ABCG2 is now a well- known 
susceptible gene for hyperuricaemia and gout, especially in the 
Japanese population.31 42 Few patients had gout before West-
ernisation of Japan about 150 years ago, which brought more 
purine- rich foods to Japan. The fact that ABCG2 also has a rela-
tionship with SUA levels might thus have caused few problems 
to Japanese people until recently. The upside of SUA elevation 
in the Japanese population might include resistance to anti-
oxidative stress, lower cancer risk, neuroprotective effect and 
longevity.43 44 Selection pressure analysis with other populations 
will also generate more information on evolutionary association 
with gout to elucidate this hypothesis.
In summary, we performed GWASs of all gout as well as of 
distinct gout subtypes, and identified multiple subtype- specific 
loci including four novel loci. Selection pressure analysis 
revealed significant enrichment of selection for the ABCG2 and 
ALDH2 loci in Japanese gout patients of each subtype. These 
findings will lead to elucidation of the molecular pathophysi-
ology of each gout/hyperuricaemia subtype and the development 
of novel subtype- specific genome tailor- made medicine/preven-
tion of gout and hyperuricaemia.
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